Abstract:Malignancies are one of the three major causes of renal recipient´s death with a functioning graft after cardiovascular diseases and infections. Among the variety of risk factors, including conventional and specific to transplant recipients, the duration of immunosuppressive therapy, the intensity of therapy, and the type of immunosuppressive agent all have an impact on development of post-transplant malignancy. The aim of our retrospective study was to document the incidence, the type of malignancies, the patient/graft survival in the group of kidney transplant recipients in Slovak Republic, and to identify the factors which influenced the outcome. We analyzed the data of 1421 patients who underwent renal transplantation from deceased or living donors in the period from 2007 to 2015 in the Slovak transplant centers. The incidence of malignant tumors was 6%, the malignancy was diagnosed in 85 patients at the age of 54.1 ± 9.8 years, more frequently in men (68.2 %; P < 0.0001). The mean time of malignancy occurrence was 45 months after transplantation. The most frequent malignancies were skin cancers- basal cell carcinoma (BCC) in 17.6%, squamous cell carcinoma (SCC) in 8.2%, and malignant melanoma (MM) in 2.4% of patients, followed by non-skin tumors such as renal cell carcinoma (RCC) in 16.5%, cancer of colon in 12.9%, prostatic cancer in 9.4%, breast cancer in 9.4%, cancer of lung in 7.1%, post-transplant lymphoproliferative disease (PTLD) in 2.4%, cancer of urine bladder in 2.4%, and cancer of sublingual gland in 1.17% of patients. Surgical treatment was used in 40% of patients, chemotherapy in 7.1%, radiotherapy in 2.4%, treatment with biological agents in 15.3%, combined therapy in 29.4% and palliative treatment in 5.9% of patients. 55.3% of patients underwent conversion from other immunosuppressive agents into mTORi at the time of malignancy occurrence. The remission was achieved in 48.2% of patients, 28.2% of patients were in the oncology treatment in the end of the year 2015, and 23.5% of patients died. There was no difference in the kidney function at the time of malignancy occurrence (s-creat 133.7 ± 59.8 µmol/l) and one year later (s-creat 131.1 ± 47.9 µmol/l) (P = 0.7768). The patients after successful treatment more frequently suffered from BCC (P = 0.0140), did not undergo palliative treatment (P = 0.0033), but were more frequently treated surgically (P < 0.0001).

Long-term survival of kidney-transplant recipient with donor-transmitted malignant melanoma after provoked rejection

Recurrent melanoma 25 years after initial diagnosis, presenting as metastatic disease early after heart transplantation

Immune-checkpoint inhibitors in renal transplanted patients affected by melanoma: a systematic review

Fighting malignancy in organ transplant recipients

Kidney Transplantation From Donors With Malignant Renal Masses: A Systematic Review

Donor-Derived Ovarian Cancer in a Male Recipient After Kidney Transplant: A Case Report

Occurrence of malignancies after kidney transplantation in adults: Slovak multicenter experience

Clinical Analysis of Malignant Tumors in Recipients of Renal Transplantation

AN ONE-CENTER EPIDEMIOGRAPHIC ANALYSIS OF MALIGNANCY IN RENAL ALLOGRAFY RECIPIENTS

Kaposi Sarcoma after Kidney Transplantation: a Case Report and Literature Review

Efficient multiple treatments including molecular targeting agents in a case of recurrent hepatocellular carcinoma, post-living donor liver transplantation

[Transplant Candidate with Cancer: Should We Proceed?]

Four-year Allograft Survival in a Highly Sensitized Combined Liver-Kidney Transplant Patient Despite Unsuccessful Anti-Hla Antibody Reduction with Rituximab, Splenectomy, and Bortezomib.

A Case Report of Successful Kidney Transplantation in a Patient With Chronic Myelogenous Leukemia (CML) Who Has Been in Remission for 15 Years on Imatinib

A Case Report of Concurrent Transplant Renal Artery Stenosis, Renal Cell Carcinoma, and Papillary Thyroid Cancer After Renal Transplantation: A Literature Review

Long-term survival after autologous peripheral blood stem cell transplantation in two patients with malignant rhabdoid tumor of the kidney

Multiple myeloma derived from a kidney transplant donor who also developed myeloma after kidney donation

Multistep tumor genetic evolution and changes in immunogenicity trigger immune-mediated disease eradication in stage IV melanoma: lessons from a single case

Long-term survival as a treatment benchmark in melanoma: latest results and clinical implications

Outcomes in solid organ transplant recipients with a pretransplant diagnosis of melanoma

[Concomitant use of nivolumab and immunosuppressants in a renal transplant patient]